Biomerica, Inc. (BMRA)
Biomerica, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $1.57, up 0.24% on the session, giving a market capitalisation of $4.9M. On trailing twelve-month figures it carries a trailing P/E of -1.50, a net margin of -96.5%. Its beta of 0.33 implies it has historically moved less than the broad market.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Biomerica, Inc. is most often compared with the following Healthcare names: